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Abstract
Background—Environmental tobacco smoke (ETS) exposure is hypothesized to influence 
survival after breast cancer, but few studies have examined this association.
Methods—A population-based cohort of women (N=1,508) diagnosed with first primary invasive 
or in situ breast cancer in 1996–1997 was interviewed shortly after diagnosis and again 
approximately 5 years later to assess ETS exposure, and women were followed for over 18 years 
using the National Death Index; 597 deaths (237 associated with breast cancer) were identified. 
Multivariable Cox regression was used to estimate adjusted hazard ratios (HR) and 95% 
confidence intervals (CI) for mortality among women with breast cancer as related to at-diagnosis 
and at-/post-diagnosis changes in ETS exposure.
Results—There was little or no association between at-diagnosis ETS exposure and all-cause 
(HR=1.04, 95% CI=0.78–1.40) or breast cancer-specific (HR=0.98, 95% CI=0.63–1.52) mortality. 
Mortality was elevated among women who reported cessation in post-diagnosis ETS exposure up 
to one year before the follow-up assessment, for all-cause (HR=1.81, 95% CI=0.87–3.74) and 
breast cancer mortality (HR=1.89, 95% CI=0.68–5.24); however, estimates were imprecise.
Conclusions—We found little evidence of an association between at-diagnosis ETS exposure 
and mortality after breast cancer. Post-diagnosis cessation of ETS exposure was positively 
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associated with mortality, although we could not rule out chance and reverse causation as possible 
explanations.
Impact—Exposure to ETS does not appear to influence mortality after breast cancer.
Keywords
environmental tobacco smoke; second-hand smoke; passive smoke; breast cancer; mortality; 
survival analysis
Introduction
Few studies (1–4) have examined whether environmental tobacco smoke (ETS) exposure 
increases the risk of mortality among women with breast cancer and no studies to date have 
prospectively examined the impact of post-diagnosis changes in ETS exposure on mortality. 
This study examined whether ETS exposure was associated with long-term all-cause and 
breast cancer-specific mortality among a population-based sample of women.
Materials and Methods
Participants of the Long Island Breast Cancer Study Project (LIBCSP), a population-based 
cohort of women newly diagnosed with breast cancer, were interviewed shortly after 
diagnosis and again about 5 years later, and now continue to be followed for vital status. 
Details of the LIBCSP have been published previously (2,5). Institutional Review Board 
approval was obtained from of all participating institutions.
Environmental Tobacco Smoke Exposure Assessment
ETS exposure was determined via structured interviews (2). Women were asked to report 
whether any members of the household smoked in their presence, the relationship of the 
smoker, the participant’s ages at first/last exposure, and any time periods the household 
member did not smoke. Duration of exposure was categorized as <15 years, ≥15–<30 years, 
and ≥30 years of exposure. Recency of exposure was categorized as <5 years, ≥5–<10 years, 
and ≥10 years.
Covariate assessment
Covariates assessed via questionnaire included: age, menopausal status, annual household 
income, education, marital status, body mass index, physical activity, intake of alcoholic 
beverages, cigarette smoking, and treatment. Estrogen receptor status and nodal involvement 
were determined by medical record. Tumor size was obtained from the NY State Cancer 
Registry.
Outcome Assessment
Vital status of the 1,508 women diagnosed with breast cancer was determined using the 
National Death Index. Follow-up for mortality occurred from the date of diagnosis in 1996–
1997 until December 31, 2014 (median=17.61 years). We identified 597 deaths; 234 were 
associated with breast cancer.
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Statistical Analysis
Using multivariable Cox proportional regression models, we estimated hazard ratios (HR) 
and 95% confidence intervals (CI) for the associations between at-diagnosis as well as at-/
post-diagnosis changes in ETS exposure and mortality following breast cancer. Models 
restricted to women with invasive cancer only yielded similar results from those of all 
women; only the latter are shown. All analyses were conducted using IBM SPSS Statistics 
Version 22.0 (IBM Corp., Armonk, NY).
In analyses of at-diagnosis ETS exposure, survival time began at the date of breast cancer 
diagnosis and ended on the date of death or, if alive, December 31, 2014. In analyses 
examining post-diagnosis ETS exposure, survival time began at the date of completion of the 
follow-up questionnaire and ended on the date of death or, if alive, December 31, 2014. 
Missing covariates were imputed in SPSS using 25 imputations with 1,000 iterations. The 
imputation models included age at diagnosis, menopausal status, income, education, marital 
status, BMI, physical activity, and alcohol intake, smoking status, post-diagnosis ETS 
exposure, disease characteristics (stage, tumor size, nodal involvement estrogen receptor 
status), treatment (radiation, chemotherapy, and hormone therapies), and the outcome (the 
event indicator and the Nelson-Aalen cumulative hazard estimator).
Results
Approximately 15% of women reported ETS exposure in the year before diagnosis and 14% 
reported current exposure at the follow-up questionnaire.
At-Diagnosis Environmental Tobacco Smoke Exposure
There was little or no association between current ETS exposure and all-cause (HR=1.04, 
95% CI=0.78–1.40) or breast cancer-specific (HR=0.98, 95% CI=0.63–1.52) mortality after 
adjustment for covariates (Table 1). Risk of mortality was slightly elevated for all-cause 
(HR=1.17, 95% CI=0.74–1.86) and breast cancer-specific (HR=1.13, 95% CI=0.57–2.27) 
mortality when we restricted the analyses to never smokers, though the corresponding 
estimates imprecise.
At-/Post-Diagnosis Environmental Tobacco Smoke Exposure
Though no associations were observed among women with ongoing ETS exposure, HRs 
were elevated 81% (HR=1.81, 95% CI=0.87–3.74) for all-cause mortality and 89% 
(HR=1.89, 95% CI=0.68–5.24) for breast cancer-specific mortality among women who 
reported cessation in post-diagnosis ETS exposure up to the year before the follow-up 
assessment (Table 2).
Discussion
Exposure to the constituents of tobacco smoke, either through active smoking or exposure to 
ETS, is hypothesized to influence breast cancer progression through several mechanisms, 
including directly by influencing cell proliferation and metastasis (6), and indirectly by 
disrupting the endocrine system (7). Additionally, because up to 70% of tar in ETS is in the 
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vapor phase, whereas all of the tar in direct smoking is in the particulate phase, ETS may be 
an important source of exposure to carcinogens since particulate smoke is cleared into the 
mouth and swallowed, but vapor phase constituents are inhaled and absorbed into the 
bloodstream and lymph system (8). Despite these hypothesized mechanisms, the few studies 
conducted to date (1–4), including the sufficiently powered study reported here, provide 
limited or no evidence of an association between ETS exposure and survival after breast 
cancer. While we observed an elevated risk of mortality among women with post-diagnosis 
cessation of ETS exposure, we could not rule out chance and reverse causation as possible 
explanations.
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